Status:
COMPLETED
Tranexamic Acid in Knee Joint Surgery
Lead Sponsor:
Andrew G Hill, MBChB, MD (Thesis), EdD, FACS, FRACS
Conditions:
Osteoarthritis
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Total knee joint replacement surgery can lead to significant blood loss, which can affect recovery after surgery. Tranexamic acid (TXA) is a medication which stops the breakdown of blood clots and the...
Detailed Description
Postoperative anaemia following elective arthroplasty can lead to prolonged hospital stay, delays in rehabilitation and is often poorly tolerated in patients with cardiovascular disease.(1) Tranexamic...
Eligibility Criteria
Inclusion
- All patients at the participating sites on the waiting list for a unilateral total knee joint replacement
Exclusion
- Patients with a history or risk of thrombosis
- Active thromboembolic disease such as deep vein thrombosis, pulmonary embolism and cerebral thrombosis
- Subarachnoid haemorrhage
- Hypersensitivity to tranexamic acid or any of its ingredients.
- Refusal of blood products
- Colour blindness
- Complex hematologic disorders requiring manipulation
- Coagulopathy
- Pregnant and Lactating Women
- Anti-coagulant therapy pre-operatively within 5 days of surgery (warfarin, dabigatran, heparin)
- Severe renal failure (eGFR \<29)
Key Trial Info
Start Date :
December 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2016
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT02278263
Start Date
December 1 2014
End Date
March 1 2016
Last Update
May 20 2020
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Auckland Hospital
Auckland, New Zealand
2
Manukau Surgery Centre
Auckland, New Zealand
3
North Shore Hospital
Auckland, New Zealand
4
Nelson Hospital
Nelson, New Zealand